Pricing Log in Create free account

Kymera Therapeutics, Inc. (KYMR) vs Vaxcyte, Inc. (PCVX)

Kymera Therapeutics, Inc. and Vaxcyte, Inc. are both Biotechnology companies. Vaxcyte, Inc. is the larger, with a market value of $10.3B against $9.0B — 1.1× the size. Vaxcyte, Inc. has the higher net margin (0.00% vs −285.3%) and the lower return on invested capital (−57.3% vs −26.7%). Across the 14 metrics below, Kymera Therapeutics, Inc. leads on 8 and Vaxcyte, Inc. on 6.

Valuation

Metric KYMR PCVX Biotechnology median
P/E n/m n/m 8.50
P/S 97.97 n/m 9.71
P/B 6.82 3.33 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 91.40 n/m 9.21
Earnings yield (3.09%) (11.99%) (33.15%)
Free cash flow yield (2.31%) (9.73%) (25.50%)

Profitability

Metric KYMR PCVX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (333.50%) 0.00% 0.00%
Net margin (285.33%) 0.00% 0.00%
Free cash flow margin (226.62%) 0.00% 0.00%
Return on equity (24.15%) (36.51%) (56.36%)
Return on assets (21.58%) (33.03%) (48.04%)
Return on invested capital (26.72%) (57.30%) 0.00%

Growth

Metric KYMR PCVX Biotechnology median
Revenue growth (TTM) 134.84% — 6.02%
EPS growth (last fiscal year) (23.83%) (48.16%) 30.26%
Revenue growth, 5-year CAGR 2.87% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KYMR PCVX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.34 5.72 4.72
Net debt to EBITDA 2.42 1.71 0.96

Dividend

Metric KYMR PCVX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KYMR PCVX Biotechnology median
Market cap 8.99b 10.27b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack